Akums’ Smartdose Technology

Akums’ Smartdose Technology: Revolutionizing Conventional Tablet Formulations

Introduction

Patients have a preference for taking medicine orally, and tablets are the most commonly used form of solid oral medication. For many years, the pharmaceutical industry has been exploring ways to improve oral medications, intending to improve their safety and efficacy, leading to higher patient adherence.

Smartdose Technology is a novel innovation in tablet formulations by Akums Drugs and Pharmaceuticals Ltd that addresses some of the key challenges faced by patients when taking medication. By decreasing the size and weight of tablets, Smartdose Technology makes it easier for people, especially the elderly or those who have trouble swallowing large tablets, to take their medication. This is a novel solution that can improve medication compliance and overall health outcomes.

Smart Tablets over Conventional Oral Dosage

Oral medication administration is based on the idea that safe swallowing is a stable function in life and that swallowing tablets and capsules is a given competence of all humans over the age of 12. Dysphagia is a quiet and hidden issue that causes dehydration, malnutrition, and pneumonia in elderly persons.

Improve patient compliance by size reduction: Smartdose technology has the potential to significantly improve patient compliance. One of the main benefits of this technology is that it reduces the size and weight of tablets, making it easier for patients to swallow their medication by improving the overall experience of taking medication. This can lead to improved patient outcomes and increased confidence in their treatment.

 

Improve product characteristics: Smartdose technology has the potential to improve the properties of a medicine in a variety of ways, resulting in higher efficacy, increased patient compliance, and improved health outcomes for patients.

Reduced disintegration time: It is critical in the treatment of diseases such as hypertension to provide quick and constant medication administration to assist manage blood pressure levels. Telmisartan tablets manufactured with Akum’s smart-dose technology ensures the rapid breakdown of tablet and faster dissolution. This smart tablet has low sodium content and dissolves faster in the body, which improves medicine absorption and efficacy, resulting in improved blood pressure management.

Improved bioavailability: This innovative technology can increase the surface area-to-volume ratio, leading to improved solubility and bioavailability of the active ingredient. This enhances the rate and amount of dissolution, resulting in improved bioavailability as more of the active substance is absorbed by the body.

 

Excipients are ingredients included in drug formulations to improve their physical and chemical characteristics. Although these ingredients are usually considered to be safe and well-tolerated, some individuals may still experience adverse effects. For example, some people may develop an allergy to certain excipients. Others may experience digestive problems, particularly those with conditions like celiac disease or diabetes.

Reduced excipient load: Akum’s SmartDose Technology was used to reduce the excipient load by more than 60% in the 5mg Dapagliflozin tablet formulation and more than 80% in the 10 mg Dapagliflozin tablet formulation.

Akum’s Smartdose Technology is an effective technology for drugs with poor solubility, stability, and bioavailability. The size reduction technology is an efficient means of enhancing the bioavailability of poorly soluble medications without changing their chemical makeup.

 

Conclusion

To accomplish the intended effect, the medicine should be delivered to its site of action at a pace and concentration that maximizes therapeutic impact while minimizing side effects. Much attention must be paid to the area of building medication delivery systems with organoleptic elegance and optimum patient compliance. In the next few years, emerging nations such as India are projected to see a greater prevalence of patient-centric research and healthcare systems.

Akums Drugs and Pharmaceuticals believes that paying more attention to dosage size reduction during the development and manufacturing of solid oral dosage forms will become standard practice, and drug product presentations in the form of multi-particulate systems or small tablets will become more common in the coming years.